Kathy de Graaf

Kathy de Graaf has a strong background in clinical pharmacology and scientific research. Kathy is currently the Director of Clinical Pharmacology at MorphoSys, a position they have held since January 2021. Prior to joining MorphoSys, Kathy was the Head of Clinical Pharmacology at Affimed from October 2019 to January 2021. Kathy also gained extensive experience at NovImmune, where they held multiple roles including Clinical Pharmacologist from February 2018 to October 2019, Junior Clinical Pharmacologist from February 2017 to January 2018, and Clinical Scientist Leader (Consultant) from September 2011 to January 2017. Kathy initially started their career as a Postdoctoral Fellow at the Hertie Institute for Clinical Brain Research from 2001 to 2007.

Kathy de Graaf has a strong educational background in the field of Chemistry and pharmacokinetics/pharmacodynamics (PK/PD) modeling and simulation. Kathy completed their Bachelor of Science (B.Sc.) degree in Chemistry from Rijksuniversitair Centrum Antwerpen, Belgium from 1988 to 1990.

Kathy then pursued a Master of Science (M.Sc.) degree in Chemistry from KU Leuven, where they studied from 1990 to 1992. Following this, they obtained a Ph.D. in Experimental Medicine from Karolinska Institutet, studying from 1995 to 2001.

In 2014, Kathy de Graaf enrolled at The University of Manchester and completed a Master of Science (MS) degree in PK and PD modeling and simulation, which they finished in 2017.

Additionally, Kathy de Graaf pursued a certification in Data Science with R Track from DataCamp. However, the specific month and year of obtaining this certification are not mentioned.